IL2 and melanoma: Evidence of an effective and durable immune response against cancer dates back more than three decades, as high-dose interleukin 2 (IL-2) therapy produced durable responses with few relapses among approximately 10% of patients with advanced renal cell carcinoma (RCC) and melanoma [11].